Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


House Energy & Commerce Democratic Leadership Seeks Hearing On Part D Waste And Fraud

This article was originally published in The Pink Sheet Daily

Executive Summary

Request follows HHS Office of Inspector General report that shows plans underestimated rebates in 2008, which led to higher beneficiary premiums.

You may also be interested in...

Mental Health Drugs Face Contracting Challenges From Part D Formulary Proposal

CMS estimates that removing antidepressants, antipsychotics and immunosuppressants from “protected class” status in Medicare Part D could save $720 million between 2016 and 2019.

Higher Part D Premiums Whet Waxman’s Appetite For HHS Price Negotiation

Increasing Part D premiums have caught the eye of Rep. Henry Waxman, who sees them as further evidence that HHS would do a better job of negotiating drug prices for Part D than the private sector

One-Quarter Of Part D Drugs Are Rebated To Plans, Rep. Waxman Reports

Twenty-seven percent of the various drug products used by Medicare Part D enrollees are subject to manufacturer rebates that reduce their price, according to a survey of the leading 12 Part D insurance providers





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts